GAS2L3 and glioblastoma: As shown in Figure S8A, the alteration frequency of these four members in the TCGA‐LGG/GBM project was lower than 1.2%, and no significant mutation of GAS2L3 was detected in the TGCG‐GBM project, while ~0.2% amplification mutations of GAS2L3 were presented in the TGCA‐GBM project.